Lisocabtagene maraleucel (Breyanzi, Bristol Myers Squibb) is indicated for the 'treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B, after two or more lines of systemic therapy'.
The dosage schedule is available in the summary of product characteristics for lisocabtagene maraleucel.
The list price of lisocabtagene maraleucel is £297,000.00 for a single infusion of chimeric antigen receptor T cells (excluding VAT; company submission).
The company has a commercial arrangement. This makes lisocabtagene maraleucel available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, the Carbon Reduction Plan for UK carbon emissions is published on Bristol Myers Squibb's webpage on sustainability.